The Impact of Advanced Age on Major Cardiovascular Events and Mortality in Patients with ST-Elevation Myocardial Infarction Undergoing a Pharmaco-Invasive Strategy

References

• Ibanez B, James S, Agewall S, et al. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J. 2018;39(2):119–177.28886621
   PubMed Web of Science ®Google Scholar
• Sharma V. Pharmaco-invasive strategy: an attractive alternative for management of ST-elevation myocardial infarction when timely primary percutaneous coronary intervention is not feasible. J Postgrad Med. 2018;64(2):73–74. doi:10.4103/jpgm.JPGM_353_1729692396
   PubMed Web of Science ®Google Scholar
• Alexander KP, Newby LK, Armstrong PW, et al. Acute coronary care in the elderly, part II: ST-segment-elevation myocardial infarction: a scientific statement for healthcare professionals from the American Heart Association Council on Clinical Cardiology: in collaboration with the Society of Geriatric Cardiology. Circulation. 2007;115(19):2570–2589. doi:10.1161/CIRCULATIONAHA.107.18261617502591
   PubMed Web of Science ®Google Scholar
• Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular clinical trials. A consensus report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736–2747. doi:10.1161/CIRCULATIONAHA.110.00944921670242
   PubMed Web of Science ®Google Scholar
• Lee PY, Alexander KP, Hammill BG, Pasquali SK, Peterson ED. Representation of elderly persons and women in published randomized trials of acute coronary syndromes. JAMA. 2001;286(6):708–713. doi:10.1001/jama.286.6.70811495621
   PubMed Web of Science ®Google Scholar
• Sinnaeve PR, Danays T, Bogaerts K, Van de Werf F, Armstrong PW. Drug treatment of STEMI in the elderly: focus on fibrinolytic therapy and insights from the STREAM trial. Drugs Aging. 2016;33(2):109–118. doi:10.1007/s40266-016-0345-626849132
   PubMed Web of Science ®Google Scholar
• Armstrong PW, Gershlick AH, Goldstein P, et al. Fibrinolysis or primary PCI in ST-segment elevation myocardial infarction. N Engl J Med. 2013;368(15):1379–1387. doi:10.1056/NEJMoa130109223473396
   PubMed Web of Science ®Google Scholar
• Regitz-Zagrosek V, Oertelt-Prigione S, Prescott E, et al.; The EUGenMed Cardiovascular Clinical Study Group. Gender in cardiovascular diseases: impact on clinical manifestations, management, and outcomes. Eur Heart J. 2016;37(1):24–34.26530104
   PubMed Web of Science ®Google Scholar
• Boucher JM, Racine N, Thanh TH, et al. Age-related differences in in-hospital mortality and the use of thrombolytic therapy for acute myocardial infarction. CMAJ. 2001;164(9):1285–1290.11341137
   PubMed Web of Science ®Google Scholar
• Stenestrand U, Wallentin L. Register of information and knowledge about Swedish Heart Intensive Care Admissions (RISK-HIA). Fibrinolytic therapy in patients 75 years and older with ST-segment-elevation myocardial infarction: one-year follow-up of a large prospective cohort. Arch Intern Med. 2003;163(8):965–971. doi:10.1001/archinte.163.8.96512719207
   PubMedGoogle Scholar
• Avezum A, Makdisse M, Spencer F, et al. Impact of age on management and outcome of acute coronary syndrome: observations from the Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2005;149:67–73. doi:10.1016/j.ahj.2004.06.00315660036
   PubMed Web of Science ®Google Scholar
• Moser DK, Kimble LP, Alberts MJ, et al. Reducing delay in seeking treatment by patients with acute coronary syndrome and stroke: a scientific statement from the American Heart Association Council on Cardiovascular Nursing and Stroke Council. Circulation. 2006;114(2):168–182. doi:10.1161/CIRCULATIONAHA.106.17604016801458
   PubMed Web of Science ®Google Scholar
• White HD. Thrombolytic therapy in the elderly. Lancet. 2000;356(9247):2028–2030. doi:10.1016/S0140-6736(00)03397-311145486
   PubMed Web of Science ®Google Scholar
• Boersma E, Maas ACP, Deckers JW, Simoons ML. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet. 1996;348(9030):771–775. doi:10.1016/S0140-6736(96)02514-78813982
   PubMed Web of Science ®Google Scholar
• Rovelli F, De Vita C, Feruglio GA, et al. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;327(8478):397–402.
   Google Scholar
• Maggioni AP, Franzosi MG, Santoro E, White H, Van de Werf F, Tognoni G. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. N Engl J Med. 1992;327(1):1–6. doi:10.1056/NEJM1992070232701011598096
   PubMed Web of Science ®Google Scholar
• Lesnefsky EJ, Lundergan CF, Hodgson JM, et al. Increased left ventricular dysfunction in elderly patients despite successful thrombolysis: the GUSTO-1 angiographic experience. J Am Coll Cardiol. 1996;28(2):331–337. doi:10.1016/0735-1097(96)00148-98800106
   PubMed Web of Science ®Google Scholar
• Thiemann DR, Coresh J, Schulman SP, Gerstenblith G, Oetgen WJ, Powe NR. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years. Circulation. 2000;101(19):2239–2246. doi:10.1161/01.CIR.101.19.223910811589
   PubMed Web of Science ®Google Scholar
• White HD, Barbash GI, Califf RM, et al. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation. 1996;94(8):1826–1833. doi:10.1161/01.CIR.94.8.18268873656
   PubMed Web of Science ®Google Scholar
• Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet. 1994;343(8893):311–322. doi:10.1016/S0140-6736(94)91161-47905143
   PubMed Web of Science ®Google Scholar